Anzeige
Mehr »
Sonntag, 26.10.2025 - Börsentäglich über 12.000 News
Das nächste Lila Sciences? Telescope Innovations ist das 30-Millionen-Dollar-Tor zu KI-gesteuerter Chemie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 931150 | ISIN: NO0010000045 | Ticker-Symbol: PHS
Frankfurt
24.10.25 | 08:02
4,385 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
PHOTOCURE ASA Chart 1 Jahr
5-Tage-Chart
PHOTOCURE ASA 5-Tage-Chart
RealtimeGeldBriefZeit
4,2504,48525.10.

Aktuelle News zur PHOTOCURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrPhotocure ASA: Invitation to presentation of third quarter 2025 financial results1
15.10.Photocure ASA: Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy1
15.10.Photocure and Intelligent Scopes Corporation partner on development of AI for blue light cystoscopy255OSLO, Norway, Oct. 15, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it has entered into a partnership with Intelligent Scopes Corporation...
► Artikel lesen
22.09.Photocure ASA - Share option grant1
04.08.PHOTOCURE: Asieris: Cevira (APL-1702) NDA Advances to Second Round of Technical Review1
04.08.Photocure ASA: Asieris: Cevira NDA Advances to Second Round of Technical Review-
30.07.Photocure ASA reports Q2 results2
PHOTOCURE Aktie jetzt für 0€ handeln
30.07.PHOTOCURE ASA Q2 Profit Retreats1
30.07.Photocure Q2 2025 presentation: Record revenue growth amid strategic expansion7
30.07.Photocure ASA: Results for the second quarter of 2025452OSLO, Norway, July 30, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 135.6 million in the second quarter of 2025 (Q2 2024: NOK 122.4 million)...
► Artikel lesen
30.07.Photocure Q2 2025: Rekordumsatz und strategische Expansion5
22.07.Photocure ASA: Invitation to presentation of second quarter and first half year 2025 financial results1
08.05.Photocure ASA reports Q1 results1
08.05.Photocure Q1 2025 presentation: 7% revenue growth amid strategic expansion initiatives5
08.05.Photocure ASA: Results for the first quarter of 2025957OSLO, Norway, May 8, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 125.3 million in the first quarter of 2025 (Q1 2024: NOK 116.8 million)...
► Artikel lesen
05.05.Photocure ASA: Annual general meeting held1
30.04.Photocure ASA: Invitation to presentation of first quarter 2025 financial results2
29.04.Photocure ASA: Bladder Cancer presentations at AUA2025: Blue Light Cystoscopy improves risk stratification and informed decision making2
26.03.Photocure appoints Jane Healy as Vice President and General Manager EMEA763OSLO, Norway, March 26, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Jane Healy as Vice President and General Manager EMEA. Ms....
► Artikel lesen
24.03.Photocure: Clinical data presentations at the European Association of Urology (EAU) 2025 congress highlight the benefits of using Blue Light Cystoscopy in bladder cancer353OSLO, Norway, March 24, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two abstract presentations at the 2025 European Association of Urology congress...
► Artikel lesen
Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1